About Morphotek
Morphotek is a Healthcare company based in Exton (United States) founded in 2000, and was acquired by Eisai in March 2007. Monoclonal antibodies against cancer, inflammatory and infectious diseases. Morphotek has raised $79.5 million across 18 funding rounds from investors including Eisai, dsm-firmenich and HHS. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include Moderna, BeiGene and Aclaris Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Morphotek develops biological-based products to treat cancer, inflammation, and infectious diseases. Has several monoclonal antibodies (mAbs) in clinical development for cancer and inflammatory disease. Its lead program, farletuzumab is for patients with platinum-sensitive, relapsed ovarian cancer (received orphan drug designation) and 1st line non-small cell lung cancer. Its other lead antibody monoclonal programs, amatuximab, and ontuxizumab. Amatuximab, ontuxizumab has received orphan drug designation for malignant pleural mesothelioma and for sarcoma respectively. Its other investigational mAbs programs are against inflammatory and infectious diseases.
- Headquarters Exton, United States
- Stage Acquired
- SectorsHealthcare
- Website morphotek.com
- Social LinkedIn
- Acquired by Eisai (Mar 2007)
Funding Insights of Morphotek
Morphotek has successfully raised a total of $79.5M across 18 strategic funding rounds. The most recent funding activity was a Grant round of $947 thousand completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $79.5M
- Total Rounds 18
- Last Round Grant — $947,000
- First Round $2M
(May 2000)
- Investors Count 15
Latest 10 of 18 funding rounds of Morphotek with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2011 | $947,000 | Grant | – | – | |
| Feb 2011 | $947,650 | Grant | – | – | |
| Sep 2009 | $843,289 | Grant | – | – | |
| Nov 2008 | $1.6M | Grant | – | – | |
| Sep 2008 | $1.25M | Grant | – | – | |
| Jun 2008 | $1.7M | Grant | – | – | |
| Feb 2008 | $1.78M | Grant | – | – | |
| Oct 2007 | $2.7M | Grant | – | – | |
| Sep 2007 | $2.3M | Grant | – | – | |
| Oct 2006 | $40M | Series D | – | Investor Growth Capital |
16 investors in total: 16 institutional.
Investors in Morphotek
Morphotek has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Eisai, dsm-firmenich and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors | investorgrowthcapital.com | New York, United States | ||
Investments are directed toward young firms in pharmaceuticals and biotech. | huntbioventures.com | Dallas, United States | ||
Life Sciences focused VC firm that does early stage investments in the US | forwardventures.com | San Diego, United States | ||
Venture capital and private equity investment firm | morgenthaler.com | Portola Valley, United States | ||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Sector-agnostic investments are made in early-stage Asia Pacific startups. | 1959 | cdibcapitalgroup.com | Taipei, Taiwan | |
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
| niaid.nih.gov | ||||
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China |
Investor details for Morphotek
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Morphotek
4 dated milestones of Morphotek across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Morphotek is founded.
- Funding First funding round of $2.0M.
- Exit Acquired by Eisai.
- Funding Latest funding round, Grant, of $947K.
Competitors of Morphotek
Morphotek has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Aclaris Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. |
Detailed competitors of Morphotek
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Morphotek
Websites that share an audience with Morphotek (morphotek.com).
Websites whose visitors overlap most with Morphotek. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novartis.com | 100% | 948.8K | #58,822 | View details | |
| amgen.com | 95% | 495.4K | #116,434 | View details | |
biopartners.ch | biopartners.ch | 84% | – | ||
pepscan.nl | pepscan.nl | 84% | – | ||
proteus.fr | proteus.fr | 84% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Morphotek
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Morphotek (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Morphotek
Complete news archive for Morphotek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Morphotek
Morphotek was founded in 2000.
Morphotek is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Morphotek is a funded company, having raised a total of $79.5M across 18 funding rounds to date. The company's 1st funding round was a Series D of $40M, raised on May 2000.
Morphotek develops biological-based products to treat cancer, inflammation, and infectious diseases. Has several monoclonal antibodies (mAbs) in clinical development for cancer and inflammatory disease. Its lead program, farletuzumab is for patients with platinum-sensitive, relapsed ovarian cancer (received orphan drug designation) and 1st line non-small cell lung cancer. Its other lead antibody monoclonal programs, amatuximab, and ontuxizumab. Amatuximab, ontuxizumab has received orphan drug designation for malignant pleural mesothelioma and for sarcoma respectively. Its other investigational mAbs programs are against inflammatory and infectious diseases.
Morphotek's top competitors include Moderna, BeiGene and Aclaris Therapeutics.
Morphotek has 16 investors. Key investors include Eisai, dsm-firmenich, HHS, Flagship Pioneering, and DARPA.
Yes. Morphotek was acquired by Eisai in March 2007.